Display options
Cite
Fatima N, Cohen DC, Sukumar G, et al. Histone deacetylase inhibitors modulate KATP subunit transcription in HL-1 cardiomyocytes through effects on cholesterol homeostasis. Front Pharmacol. 2015;6:168doi: 10.3389/fphar.2015.00168.
Fatima, N., Cohen, D. C., Sukumar, G., Sissung, T. M., Schooley, J. F., Haigney, M. C., Claycomb, W. C., Cox, R. T., Dalgard, C. L., Bates, S. E., & Flagg, T. P. (2015). Histone deacetylase inhibitors modulate KATP subunit transcription in HL-1 cardiomyocytes through effects on cholesterol homeostasis. Frontiers in pharmacology, 6168. https://doi.org/10.3389/fphar.2015.00168
Fatima, Naheed, et al. "Histone deacetylase inhibitors modulate KATP subunit transcription in HL-1 cardiomyocytes through effects on cholesterol homeostasis." Frontiers in pharmacology vol. 6 (2015): 168. doi: https://doi.org/10.3389/fphar.2015.00168
Fatima N, Cohen DC, Sukumar G, Sissung TM, Schooley JF, Haigney MC, Claycomb WC, Cox RT, Dalgard CL, Bates SE, Flagg TP. Histone deacetylase inhibitors modulate KATP subunit transcription in HL-1 cardiomyocytes through effects on cholesterol homeostasis. Front Pharmacol. 2015 Aug 13;6:168. doi: 10.3389/fphar.2015.00168. eCollection 2015. PMID: 26321954; PMCID: PMC4534802.
Copy Download .nbib Format: NLM
Share it on

Front Pharmacol. 2015 Aug 13;6:168. doi: 10.3389/fphar.2015.00168. eCollection 2015.

Histone deacetylase inhibitors modulate KATP subunit transcription in HL-1 cardiomyocytes through effects on cholesterol homeostasis.

Frontiers in pharmacology

Naheed Fatima, Devin C Cohen, Gauthaman Sukumar, Tristan M Sissung, James F Schooley, Mark C Haigney, William C Claycomb, Rachel T Cox, Clifton L Dalgard, Susan E Bates, Thomas P Flagg

Affiliations

  1. Department of Anatomy, Physiology and Genetics, F. Edward Hebert School of Medicine, Uniformed Services University of the Health Sciences Bethesda, MD, USA.
  2. Developmental Therapeutic Branch, National Cancer Institute, National Institutes of Health Bethesda, MD, USA.
  3. Department of Medicine, F. Edward Hebert School of Medicine, Uniformed Services University of the Health Sciences Bethesda, MD, USA.
  4. Department of Biochemistry and Molecular Biology, LSU Health Sciences Center New Orleans, LA, USA.
  5. Department of Biochemistry, F. Edward Hebert School of Medicine, Uniformed Services University of the Health Sciences Bethesda, MD, USA.

PMID: 26321954 PMCID: PMC4534802 DOI: 10.3389/fphar.2015.00168

Abstract

Histone deacetylase inhibitors (HDIs) are under investigation for the treatment of a number of human health problems. HDIs have proven therapeutic value in refractory cases of cutaneous T-cell lymphoma. Electrocardiographic ST segment morphological changes associated with HDIs were observed during development. Because ST segment morphology is typically linked to changes in ATP sensitive potassium (KATP) channel activity, we tested the hypothesis that HDIs affect cardiac KATP channel subunit expression. Two different HDIs, romidepsin and trichostatin A, caused ~20-fold increase in SUR2 (Abcc9) subunit mRNA expression in HL-1 cardiomyocytes. The effect was specific for the SUR2 subunit as neither compound causes a marked change in SUR1 (Abcc8) expression. Moreover, the effect was cell specific as neither HDI markedly altered KATP subunit expression in MIN6 pancreatic β-cells. We observe significant enrichment of the H3K9Ac histone mark specifically at the SUR2 promoter consistent with the conclusion that chromatin remodeling at this locus plays a role in increasing SUR2 gene expression. Unexpectedly, however, we also discovered that HDI-dependent depletion of cellular cholesterol is required for the observed effects on SUR2 expression. Taken together, the data in the present study demonstrate that KATP subunit expression can be epigenetically regulated in cardiomyocytes, defines a role for cholesterol homeostasis in mediating epigenetic regulation and suggests a potential molecular basis for the cardiac effects of the HDIs.

Keywords: Abcc8; Abcc9; SREBP; cholesterol; epigenetics; romidepsin

References

  1. Nat Rev Drug Discov. 2014 Sep;13(9):673-91 - PubMed
  2. Front Genet. 2014 Sep 24;5:311 - PubMed
  3. Hypertension. 2010 Sep;56(3):437-44 - PubMed
  4. Pharmacol Ther. 2008 Oct;120(1):54-70 - PubMed
  5. Cardiovasc Res. 1999 Mar;41(3):629-40 - PubMed
  6. Expert Opin Drug Saf. 2008 Jan;7(1):53-67 - PubMed
  7. J Mol Cell Cardiol. 2010 Jan;48(1):152-60 - PubMed
  8. Physiol Rev. 2010 Jul;90(3):799-829 - PubMed
  9. Cardiovasc Res. 2007 Dec 1;76(3):473-81 - PubMed
  10. Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):2979-84 - PubMed
  11. J Clin Oncol. 2005 Jun 10;23(17):3923-31 - PubMed
  12. Science. 1995 Nov 17;270(5239):1166-70 - PubMed
  13. J Physiol. 1992 Feb;447:649-73 - PubMed
  14. J Clin Oncol. 2012 Feb 20;30(6):631-6 - PubMed
  15. Biochem Biophys Res Commun. 2007 Aug 31;360(3):593-9 - PubMed
  16. Front Pharmacol. 2013 Apr 15;4:44 - PubMed
  17. Circ Res. 2000 Nov 10;87(10):837-9 - PubMed
  18. PLoS One. 2013;8(1):e53394 - PubMed
  19. J Clin Invest. 2002 Feb;109(4):509-16 - PubMed
  20. Clin Cancer Res. 2002 Mar;8(3):718-28 - PubMed
  21. Circulation. 1993 Oct;88(4 Pt 1):1845-51 - PubMed
  22. Trends Endocrinol Metab. 2012 Feb;23(2):65-72 - PubMed
  23. Annu Rev Pharmacol Toxicol. 2012;52:303-19 - PubMed
  24. Circ Res. 2008 Feb 1;102(2):e20-35 - PubMed
  25. Oncologist. 2007 Oct;12(10):1247-52 - PubMed
  26. Circulation. 2006 Jun 6;113(22):2579-88 - PubMed
  27. Circ Res. 1991 Jan;68(1):280-7 - PubMed
  28. Drugs. 2009 Oct 1;69(14):1911-34 - PubMed
  29. Am J Physiol Heart Circ Physiol. 2014 Feb;306(3):H405-13 - PubMed
  30. Clin Cancer Res. 2008 Feb 1;14(3):804-10 - PubMed
  31. Clin Cancer Res. 2006 Jun 15;12(12):3762-73 - PubMed
  32. Clin Cancer Res. 2015 Jun 15;21(12):2666-70 - PubMed
  33. Mol Endocrinol. 2002 May;16(5):1097-107 - PubMed
  34. Diabetes. 1998 Aug;47(8):1274-80 - PubMed
  35. Circ Res. 2008 Dec 5;103(12):1458-65 - PubMed
  36. Cell. 2007 Feb 23;128(4):693-705 - PubMed
  37. Bioinformatics. 2006 Dec 1;22(23):2926-33 - PubMed
  38. Clin Genitourin Cancer. 2006 Jun;5(1):57-60 - PubMed
  39. Neuron. 1996 May;16(5):1011-7 - PubMed
  40. J Clin Invest. 2008 Jan;118(1):259-71 - PubMed
  41. J Biol Chem. 1999 Jun 25;274(26):18261-70 - PubMed
  42. Expert Rev Anticancer Ther. 2015;15(7):737-48 - PubMed
  43. Cardiovasc Res. 1986 Oct;20(10):740-51 - PubMed
  44. Proc Natl Acad Sci U S A. 2011 Apr 5;108(14):5620-5 - PubMed
  45. PLoS One. 2012;7(7):e41533 - PubMed
  46. Circulation. 2014 Mar 11;129(10):1139-51 - PubMed
  47. Proc Natl Acad Sci U S A. 1972 Dec;69(12):3795-9 - PubMed
  48. Circulation. 2006 Jan 3;113(1):51-9 - PubMed
  49. Circulation. 1999 Oct 12;100(15):1660-6 - PubMed
  50. Genomics. 1995 Nov 1;30(1):102-4 - PubMed
  51. Clin Cancer Res. 2013 Jun 1;19(11):3095-104 - PubMed
  52. J Biol Chem. 1999 May 7;274(19):13656-65 - PubMed
  53. Blood. 2011 Jun 2;117(22):5827-34 - PubMed
  54. Clin Cancer Res. 2006 Jul 1;12(13):3997-4003 - PubMed
  55. J Mol Cell Cardiol. 2008 Dec;45(6):715-23 - PubMed
  56. Trends Cardiovasc Med. 2004 Feb;14 (2):66-72 - PubMed
  57. J Biol Chem. 2001 Nov 30;276(48):44976-83 - PubMed
  58. Am J Physiol Heart Circ Physiol. 2007 Jul;293(1):H836-45 - PubMed
  59. Cardiol J. 2012;19(4):434-8 - PubMed
  60. Proc Natl Acad Sci U S A. 2011 Mar 8;108(10):4123-8 - PubMed

Publication Types